Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on March 20th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Medtronic Price Performance

Shares of MDT traded down $0.09 during mid-day trading on Tuesday, reaching $86.19. 1,024,627 shares of the company’s stock were exchanged, compared to its average volume of 8,266,311. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a 50-day simple moving average of $94.18 and a two-hundred day simple moving average of $96.19. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a market cap of $110.66 billion, a price-to-earnings ratio of 24.02, a PEG ratio of 2.24 and a beta of 0.75.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Institutional Investors Weigh In On Medtronic

A number of institutional investors have recently modified their holdings of MDT. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC acquired a new stake in Medtronic during the third quarter worth about $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic during the fourth quarter worth about $27,000. Anfield Capital Management LLC raised its stake in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Finally, Monetary Solutions Ltd acquired a new stake in Medtronic during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MDT has been the subject of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Truist Financial reduced their target price on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Citigroup cut their price objective on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Evercore cut their price objective on shares of Medtronic from $115.00 to $108.00 and set an “outperform” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $109.10.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Citigroup cut its price target to $110 but maintained a Buy rating, signaling continued analyst confidence in Medtronic’s longer‑term growth despite the lowered target. Article Title Article Title
• Positive Sentiment: Evercore lowered its target to $108 but kept an Outperform rating, implying upside remains meaningful even after the revision. Article Title Article Title
• Positive Sentiment: Argus trimmed its target from $125 to $115 but retained a Buy rating, another vote of confidence that the business fundamentals support upside over time. Article Title Article Title
• Neutral Sentiment: Corporate/sector news unrelated to Medtronic: Inogen named Vafa Jamali to its board — not material to MDT fundamentals. Article Title
• Negative Sentiment: Stifel lowered its target to $95 and kept a Hold rating; the cut and commentary highlight caution around near‑term catalysts and limit upside expectations. Article Title
• Negative Sentiment: A TipRanks piece and analyst commentary emphasize that MiniMed IPO dilution and the diabetes spin‑off may constrain near‑term upside, which supports Hold ratings and keeps pressure on the stock until clarity on transaction timing/terms. Article Title

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).